healthtekpak

  From a debt-ridden company to making a turnaround and now raking in profits, Orchid Pharma is a story worth emulating. Taken over by the Dhanuka Group in March 2020, Orchid Pharma reported a 36% surge in total revenue from operations while the EBITDA jumped by 104% over the quarter ending September 2021, according to the 2022 Q2 results posted in Medical Dialogues. Comprehensive loss for FY22 stood at Rs 0.53 crore, compared to a loss of Rs 115.87 crore in the previous year, Business Standard reported. Orchid Pharma is focusing majorly on a molecule developed in-house – Enmetazobactam, a BLI (Beta-lactamase Inhibitor) used in combination with beta-lactam antibiotic cefepime, Business Standard reported, quoting Manish Dhanuka, managing director of the Chennai-based Orchid Pharma. An injectable product, it is highly effective in treating complicated urinary tract infections, and completed global clinical trials, Dhanuka told the newspaper. India’s market for anti-infectives – medici

  At a global webinar organized recently to mark the ongoing World Antimicrobial Awareness 18-24 November, the Centre for Science and Environment ( CSE ), a Delhi-based non-profit, made a strong pitch for introducing ethnoveterinary medicines (EVM) as an effective alternative to antibiotics for the dairy sector. EVM involves the use of traditional and herbal preparations in treating diseases of cattle. CSE’s contention is based on the encouraging results of an ongoing project on EVM led by the National Dairy Development Board (NDDB). Unlike Covid-19, AMR is a silent pandemic, killing many every day across the world. A big concern is antibiotic resistance in particular, which means that antibiotics are becoming ineffective to treat bacterial infections. It is a growing global public health crisis that can also impact food security, livelihood, and development. Antibiotic misuse and overuse in producing food from animals are major causes of rising AMR. “The world wants to save antibioti